- Alternative Medicine
- Mesothelioma Cure
- Mesothelioma Research
- Mesothelioma Doctors
- Mesothelioma Cancer Centers
- Mesothelioma Clinical Trials
Over 30 Billion dollars in trust fund money has been set aside for asbestos victims.
Get a Free copy of Surviving Mesothelioma, Lean on Me, or 100 Questions & Answers About Mesothelioma
Mesolink.org now offeres Free Assistance with VA Claims and other benefits.
Dr. Daniel H Sterman
Contact Information
- 833 West Gates Building, Philadelphia, Pennsylvania 19104
- (215) 614-0984
- sterman@mail.med.upenn.edu
Pennsylvania has the third highest number of diagnosed mesothelioma cases in the United States, and ranks seventh in the number of mesothelioma mortalities. Fortunately for state residents who have been exposed to asbestos, there are a number of first-rate medical centers and physicians providing specialized care and innovative treatments for mesothelioma sufferers. One such provider is Dr. Daniel Sterman, the Clinical Director of the University of Pennsylvania Medical Center’s Thoracic Oncology Gene Therapy Program. Gene therapy is an innovative treatment approach that explores the use of gene and vaccine therapies in patients who have been diagnosed with a wide range of thoracic malignancies including mesothelioma.
Dr. Sterman’s specific clinical interests lie in the translation of laboratory discoveries in molecular medicine to actual therapies for thoracic malignancies. Since 1998, he has been the principal investigator of ongoing clinical trials funded by the National Cancer Institute, as well as another clinical trial investigating the use of Ad.IFN-beta gene therapy with patients suffering from mesothelioma and other metastatic pleural diseases. With other colleagues in the University of Pennsylvania’s Thoracic Oncology Research Group, he is conducting Phase I clinical trials examining interferon-alpha gene delivery systems, with the intent of using this experimental treatment in conjunction with more conventional chemotherapies.
Dr. Sterman received an undergraduate degree in European History from Brown University in 1985. He graduated from Cornell University Medical College in 1989, and between 1989 and 1992, completed an internship and residency in Internal Medicine at the Hospital of the University of Pennsylvania. From 1992 to 1993, he was an instructor of Emergency Medicine at the Hospital of the University of Pennsylvania, before leaving to pursue fellowship training in both Pulmonary Medicine and Critical Care Medicine at the University of Pennsylvania Medical Center from 1993 to 1997. Following that appointment, he became a Postdoctoral Research Fellow in Penn’s Thoracic Oncology Research Laboratory, staying on for two years during which time he received a National Institute of Health Clinical Associate Physician Award. He joined the University of Pennsylvania Medical Center’s faculty in 1997 as an Assistant Professor of Medicine in the Pulmonary Division.
Currently Dr. Sterman holds appointments as both Associate Professor of Medicine and Associate Professor of Medicine in Surgery at the University of Pennsylvania Medical Center. In addition, Dr. Sterman is the Director of the PENN Interventional Pulmonology Program, and Clinical Director of the Thoracic Oncology Gene Therapy Program of the Center for Lung Cancer and Related Disorders. Dr. Sterman is board certified in Critical Care Medicine, Internal Medicine, and Pulmonary Medicine.
In conjunction with his research activities, Dr. Sterman has published a number of peer-reviewed articles in such journals as Human Gene Therapy, Chest, The Journal of Clinical Oncology, the Journal of the National Cancer Institute and The New England Journal of Medicine. Dr. Sterman has also presented his groundbreaking research at many conferences and symposiums, both at home and abroad.